Presented by Matthew Rettig, MD
About the Lecture
Prostate cancer is the most common cancer diagnosed in men in the United States. Over the last decade there has been an increasing shift in decision making regarding when to screen and when to treat prostate cancer. This is largely because most men with prostate cancer will die with their disease not from their disease. That being said there continues to be a population of men for whom screening is not appropriate and/or where traditional treatments of surgery, radiation and hormone therapy may not be definitive. This lecture addresses the range of choices that are made with particular focus on what happens once treatment is deemed necessary and appropriate. This presentation will cover the wide range of treatments including those for men who have disease that progresses despite surgical and radiation therapy interventions. The combinations of treatment approaches – both traditional and cutting edge will be discussed including immunotherapies, hormonal approaches, chemotherapy and clinical trials.
About the Speaker
Matthew Rettig, M.D. is a Professor in the Departments of Medicine and Urology, and is the Medical Director of the Prostate Cancer Program of the Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. After receiving his medical degree from Duke University, Dr. Rettig completed his internal medicine residency at the University of Washington before going on to a hematology-oncology fellowship at UCLA. As a medical oncologist, he focuses on the management of genitourinary malignancies with a focused clinical emphasis on advanced prostate cancer. Dr. Rettig has both a clinical and bench research program. As the director of the clinical trials program in prostate cancer at UCLA, he conducts multiple prostate cancer clinical trials that span the spectrum of the states of the disease: from neoadjuvant therapies to post-chemotherapy, castration-resistant disease. Dr. Rettig’s bench research program, which is funded by the NIH, Department of Defense, the Prostate Cancer Foundation, and the Department of Veterans Affairs, is focused on identifying new targets and new drugs for therapeutic implementation in castration-resistant prostate cancer and clear cell renal cell carcinoma.